Exosomes are nano-sized extracellular vesicles released by many cells that contain 35 molecules characteristic of their cell-of-origin, including microRNA. Exosomes released 36 by glioblastoma cross the blood-brain-barrier into the peripheral circulation, and carry 37 molecular cargo distinct to that of 'free-circulating' miRNA. In this pilot study, serum 38 exosomal-microRNAs were isolated from glioblastoma (n=12) patients and analyzed 39 using unbiased deep sequencing. Results were compared to sera from age-and gender-40 matched healthy controls, and to grades II-III (n=10) glioma patients. Significant 41 differentially expressed microRNAs were identified, and the predictive power of 42 individual and subsets of microRNAs were tested using univariate and multivariate 43 analyses. Additional sera from glioblastoma patients (n=4) and independent sets of 44 healthy (n=9) and non-glioma (n=10) controls were used to further test the specificity and 45 predictive power of this unique exosomal-microRNA signature. Twenty-six microRNAs 46 were differentially expressed in serum exosomes from glioblastoma patients' relative to 47 59
healthy controls. Random forest modeling and data partitioning selected seven miRNAs 48 (miR-182-5p, miR-328-3p, miR-339-5p, miR-340-5p, miR-485-3p, miR-486-5p and 49 miR-543) as the most stable for classifying glioblastoma. Strikingly, within this model, 50 six iterations of these miRNA classifiers could distinguish glioblastoma patients from 51 controls with perfect accuracy. The seven-miRNA panel was able to correctly classify 52 all specimens in validation cohorts (n=23). Also identified were 23 dysregulated 53 miRNAs in IDH MUT gliomas, a partially overlapping yet distinct signature of lower 54 grade glioma. Serum exosomal-miRNA signatures can accurately diagnose glioblastoma 55 preoperatively. miRNA signatures identified are distinct from previously reported 'free-56 circulating' miRNA studies in GBM patients, and appear to be superior. 57
INTRODUCTION
Exosomes are nano-sized (30-100 nm) membrane-bound extracellular vesicles released by 84 all cells in both health and disease, and there is growing interest in their use as non-85 invasive biomarkers for disease diagnosis and monitoring of disease recurrence 2 . GBM-86 derived exosomes circulate in the peripheral blood of patients, and can contain diagnostic 87 nucleic acid 3 . We recently described a GBM exosome protein signature 4 and also showed 88 that GBM exosomes contain abundant, selectively packaged small non-coding RNAs 89 (sncRNAs) 5 . Using unbiased sncRNA deep sequencing, we identified several unusual 90 and/or completely novel sncRNAs within GBM exosomes in vitro as well as an 91 enrichment of microRNA (miRNA) implicated in oncogenesis, including miR-23a, miR-92 30a, miR-221 and miR-451 5 . Thus, while GBM exosomal miRNA contents broadly 93 reflect their cell of origin, there is a unique profile of miRNAs within exosomes. 94 95 Some studies of exosomal miRNA in GBM patients have already been reported; these 96 studies utilized methods that focused on pre-defined and relatively small groups of 97 miRNA species. One previous study found that miR-21 levels in CSF exosomes of GBM 98 patients were up-regulated 10-fold compared to controls 6 , while another reported that 99 serum exosomal miR-320, mir-547-3p, and RNU6-1 were significantly associated with 100 GBM diagnosis, as well as outcome (RNU6-1) 7 . However, to date no comprehensive 101 analysis of the entire miRNA repertoire of serum exosomes in glioma patients has been 102 performed. Here, we have used unbiased next generation sequencing and an integrative 103 bioinformatics pipeline 8 to assay the complete repertoire of exosomal-associated miRNAs 104 in the serum of patients with glioblastoma, lower grade gliomas, and healthy controls. We 105 describe a novel miRNA signature within serum exosomes that is highly predictive of pre-106 operative GBM diagnosis. Furthermore, we show that this approach has potential for 107 describing unique miRNA signatures for distinct glioma entities. 108 6 discovery set of differentially expressed miRNA biomarkers. miRNA biomarkers were 134 identified if their differential expression met a fold change≥2 in either direction and 135 unadjusted p-values≤0.05 in all statistical tests applied. Using this approach, we identified 136 26 miRNAs significantly dysregulated between healthy controls and GBM patients 137 ( 
Functional analysis of dysregulated miRNAs in GBM 168
We explored biological and canonical pathways associated with exosomal miRNAs 169 changing in GBM patient sera relative to healthy controls. The identities of 44 miRNAs 170 (p-value≤0.05 in all three tests; no fold change restriction) were uploaded into the IPA 171 environment to analyze molecular pathways overrepresented in their targets. The 172 dysregulated miRNAs target mRNAs that are significantly associated with 'cancer' 173 
Selection of signature miRNA classifiers for preoperative GBM diagnosis 180
The predictive power of each miRNA was estimated using LR models, in which 181 individual miRNA expression profiles were used as predictors. ROC curves were 182 determined and AUROC measures were ≥0.74 across the 26 dysregulated miRNAs. 183
The 95% confidence intervals corresponding to AUROC estimates did not contain the 184 null hypothesis value (AUROC=0.5 for a random prediction) indicating that all 26 185 miRNAs are statistically accurate univariate diagnostic predictors of GBM ( Table 2 ; 186 Supp. Fig.2) . In silico validation by LOO-CV correctly identified the test sample on 187 average 83% of the time (range 77-89%). We then used partitioning (70% training and 188 30% test) and Random Forest multivariate modeling to determine whether expression 189 patterns of a subset of differentially expressed miRNAs could improve the predictive 190 power. Using these methods, seven miRNAs (miR-182-5p, miR-328-3p, miR-339-5p, 191 miR-340-5p, miR-485-3p, miR-486-5p and miR-543) distinguished GBM patients from 192 healthy subjects in more than 75% of the random data partitions and were selected as 193 the most 'stable' miRNA classifiers ( Fig.3a-b ). The RF model was repeated using all 194 iterations of the seven most stable miRNAs and achieved an overall predictive power 195 of 91.7% for classifying GBM patients from healthy controls (Fig.3c ). The diagnostic 196 accuracies of all possible combinations of the seven miRNAs were determined using 197 AUROC measures along with the corresponding 95% confidence intervals ( Fig.3d ; 198 Supplementary Table 5 ). Strikingly, six miRNA combinations were able to distinguish 199 GBM patients from healthy controls with perfect accuracy (Fig. 3e) . 200
201
To assess the temporal stability of the GBM miRNA signature in the same patients, we 202 tested preoperative sera collected at a GBM recurrence (GBM1 patient relapsed and 203 required additional surgery after 8 months) and from an earlier GBM lesion (excised 4.6 204 months before GBM12; Table 1B ). Using the panel of seven exosomal miRNAs, both 205 GBM1-relapse and GBM12-prior were classified as GBM, in line with diagnostic 206 histopathology. We also tested two independent samples, including a patient diagnosed 207 with IDH MUT GBM (GBM13) and a patient diagnosed with 'high-grade glioma' based on 208
repeat MRIs and overall survival of 8.1 months (GBM14; see Table 1B ). Both GBM13 209 and GBM14 were classified as GBM using the miRNA panel. 210
211
To further test the specificity of the GBM miRNA signature, we assessed its ability to 212 distinguish GBM patients from additional healthy subjects and non-glioma disease 213 controls. The panel accurately classified all additional healthy subjects (n=9 ; Table 1B) as 214 well as a patient with ganglioglioma WHO (2016) grade I, a slow-growing, benign brain 215 tumor with glioneuronal components (GIC-1). Next, we assessed the impact of 216 neuroinflammatory disease processes on the specificity of our exosomal miRNA panel 217 ability. The bioinformatics analysis above showed that dysregulated miRNAs also target 218 mRNAs significantly associated with autoimmune rheumatoid arthritis and broadly to 219 'neurological disease' (Fig. 2-b) . Our GBM miRNA panel was used to discriminate 220 patients with the inflammatory autoimmune disease, multiple sclerosis (MS). Sera were 221 sampled from MS patients with active gadolinium enhancing demyelinating lesions, either 222 untreated or receiving immunomodulatory therapies (n=9; Table 1B ). All MS patients 223 were classified as controls, indicating the robustness of our exosomal miRNA signature 224 for GBM identification. 225
Insert Figure 3 here 226
miRNAs dysregulated in IDH-mutant grade II-III gliomas provide additional markers 228 for glioma severity and IDH mutational status 229
We then compared serum exosome miRNA profiles between IDH MUT grade II-III glioma 230 patients (n=10; mean age=42.7) and matched healthy controls (n=10; mean age=42.9; see 231 Table 1B ) and identified 23 differentially expressed miRNAs (fold change≥2; unadjusted 232 p<0.05 in all three tests; Supp. Table 4b. ). Of these, 12 miRNAs were shared with the 233 GBM analysis and showed the same direction of change ( Fig. 4-a) . AUROC curve 234 measures were ≥0.78 (average 0.88) across the 23 dysregulated miRNAs, and LOO-CV 235 correctly identified the test sample on average 83% of the time (range 77-88%; 236
Supp. Table 5a .; Supp. Fig. 3a-b) . RF modeling performed on partitioned data selected 237 miR-7d-3p, miR-98-5p, miR-106b-3p, 130b-5p and 185-5p as the most stable features 238 for classifying grade II-III glioma patients from healthy participants, with a predictive 239 power of 75.0% (Fig. c-1.; Suppl.Fig.3c) . The most stable miRNAs for classifying GII-240 III IDH MUT from healthy controls were distinct from GBM IDH WT signature miRNAs 241 ( Fig.s 4b-1 and 4b-2 ).
243
The sncRNA data was further interrogated to ascertain whether a subset of miRNAs 244 showed potential for distinguishing glioma disease severity or IDH mutational status. 245
Direct comparisons between GBM IDH WT and GII-III IDH MUT patients revealed 13 246 differentially expressed miRNAs (fold change≥2; unadjusted p<0.05 in all three tests; 247 ( Fig. 4c-1 Fig. 4a-b) . Numbers of 250 significant miRNA were too few to perform partitioning, so a single RF model was 251 constructed from all 13 dysregulated miRNAs that showed an estimated predictive power 252 of 77.4% (Fig. 4c-2. ) Interestingly, three of the top four features that discriminate GBM 253 IDH WT from GII-III IDH MUT are members of the GBM miRNA signature (i.e., miR-254 543, miR-485-3p and miR-486-3p), changing only in GBM patient sera relative to 255 healthy participants (indicated by asterisks in Fig. 4) . circulating' studies. This is consistent with the notion that exosomes represent a distinct 279 pathway of nucleic acid release from cells, and contain selectively packaged miRNA 280 species 5 . We have previously shown the effects of RNAse pre-treatment of serum prior to 281 exosome isolation, as performed in this study, drastically alters the miRNA profiles 282 identified, presumably due to eradication of co-precipitated 'free-circulating' miRNAs 8 . 283
Moreover, normalization of deep sequencing data is not dependant on comparison to a 284 reference signal or housekeeping gene, potentially reducing variability in data analysis. 285 286 Functional pathway analysis of mRNA species targeted by exosomal miRNAs 287 dysregulated in GBM patient sera showed highly significant associations to specific GBM 288 molecular pathways. This provides confidence that the miRNA biomarkers resolved by 289 our methods are relevant to this particular disease setting. Previous studies have identified 290 roles for all seven GBM miRNA classifiers in various aspects of glioma and GBM 291 biology. miR-182, detected here in significantly higher levels in GBM sera, was proposed 292 as a marker of glioma progression, critical for glioma tumorigenesis, tumor growth and 293 survival in vitro 11,12 , with high miR-182 tissue expression observed in GBM 13 There is more than one pathological route to a GBM; primary and secondary GBMs are 319 distinct entities with IDH mutations considered a genetic signpost 29 . The only patients 320
where early detection of a GBM tumor is likely are arguably those with diffuse and 321 anaplastic (grade II-III) gliomas who progress with a secondary GBM recurrence 322 (IDH MUT ). Accordingly, the identification of reliable and readily accessible circulating 323 progression markers is an important step towards precision medicine for patients 324 diagnosed with low grade gliomas. While the GBM miRNA signature was described in 325 serum exosomes from IDH WT GBM patients, it was also able to categorize a patient with 326 IDH MUT GBM (GBM13) from healthy participants. It is worth noting that miRNA 327 members of the GBM signature panel (specifically, increased miR-182-5p, decreased 328 miR339-5p and miR-340-5p) were also identified in the IDH MUT GII-III comparative 329 analysis. Whether these miRNA changes are related to IDH mutational status, glioma 330 grade, or a combination of the two, cannot be delineated here. However, our multivariate 331 modeling did identify distinct panels of miRNAs for classifying GBM and glioma patients 332 from their corresponding matched healthy control cohorts. Moreover, three GBM 333 signature panel miRNAs that were unique to the GBM vs control comparative analysis 334 (increased miR-486-5p and decreased miR-485-3p and miR-543) were among the top 335 four features that distinguish GBM IDH WT from GII-III IDH MUT and therefore, might 336 be specific for GBM IDH WT (indicated by asterisks in Fig.4) . These encouraging results 337 demonstrate the potential for exosomal miRNA profiles to be used for glioma subtyping 338 and grading, including the determination of mutational states. Expansion of these 339 discovery analyses to include well defined cohorts of glioma subtypes with sufficient n, 340 will likely resolve biomarkers of more nuanced specificity. 341 342 343 SUMMARY 344
In summary, we have described a serum exosomal miRNA signature that can accurately 345 predict a GBM diagnosis, preoperatively. This pilot study demonstrates that exosomal 346 associated miRNAs have exceptional utility as biomarkers in the glioma disease setting. If 347 these exosomal biomarkers are able to offer non-invasive, early indications of tumor 348 progression and/or recurrence, they are likely to have significant clinical utility. These 
Data pre-processing, differential expression analysis and pathway analysis 434
Data pre-processing was performed using a pipeline comprising of adapter trimming 435 (cutadapt), followed by genome alignment to human genome hg 19 using Bowtie (18 bp 436 seed, 1 error in seed, quality score sum of mismatches<70). Where multiple best strata 437 alignments existed, tags were randomly assigned to one of those coordinates. Tags were 438 annotated against mirBase 20 and filtered for at most one base error within the tag. Counts 439 for each miRNA were tabulated and adjusted to counts per million miRNAs passing the 440 mismatch filter. All samples achieved miRNA read counts >45,000 read counts and 441 miRNAs with low abundance (<50 read counts across more than 20% of samples) were 442 removed. Differential expression analysis was performed using three different statistical 443 hypothesis tests including a non-parametric two-sample Wilcoxon test and two parametric 444 tests-Student's t-test, and an Exact test (implemented in Bioconductor EdgeR), which 445 tests for differences between the means of two groups of negative-binomially distributed 446 counts. Benjamini & Hochberg adjusted p-values were also calculated. Data pre-447 processing and differential expression analysis were performed using Bioconductor and R 448 statistical packages. Pathway analysis was performed using Ingenuity® software 449 (Ingenuity Systems, USA; http://analysis.ingenuity.com). MicroRNA target filters were 450 applied to significant, differentially expressed miRNAs (unadjusted p-value≤0.05 in all 451 three statistical methods) and mRNA target lists were generated based on highly predicted 452 or experimentally observed confidence levels. Core expression analyses were performed 453 with default criteria to determine the most significant functional associations (biological 454 and canonical pathways) of mRNAs targeted by dysregulated miRNAs. 455 456
Univariate analysis 457
We performed logistic regression (LR) and receiver operator characteristic (ROC) 458 analysis to assess the predictive power of individual miRNAs between the two groups of 459 interest. LR was used to identify linear predictive models with each miRNA as the 460 univariate predictor. The quality of each model was depicted by the corresponding ROC 461 curve, which plots the true positive rate (i.e., sensitivity) against the false-positive rate 462 (i.e., 1-specificity). The area under the ROC curve (AUROC) was then computed as a 463 measure of how well each LR model can distinguish between two diagnostic groups. The 464 95% confidence intervals (CI) of AUROC measures were estimated using Delong 465 method 34 to assess the significance of a model's predictive power as compared to a 466 random trial (i.e., AUROC = 0.5). We then used leave-one- 
